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Abstract
In this work we analysed, by immunohisto-
chemistry, a series of brain tumors to detect
the levels and cellular distribution of Hsp60
and Hsp70. We found that Hsp60 levels were
significantly higher than those of Hsp70 in
neuroepithelial tumors, while levels of both
molecules were not significantly different from
each other in meningeal neoplasms. In partic-
ular, Hsp60 immunopositivity was present
mainly at the cytoplasmic level, while Hsp70
immunopositivity was found both in the cyto-
plasm and in the nucleus of tumor cells. The
levels of these molecules in healthy control
cells were always very low. Finally, Hsp60 and
Hsp70 levels did not correlate with the differ-
ent types (WHO grade) of neoplasm. Our
results are partially in agreement with previ-
ous studies and suggest that Hsp60 is not
increased by a passive phenomenon (e.g., due
to the stress caused by the peritumor environ-
ment on cancer cells) but may be actively
implicated in tumor progression, e.g. inhibit-
ing tumor cell death or antitumor immune sys-
tem response, as already postulated in vitro.
We also briefly discuss the most recent publi-
cations on the extramitochondrial localization
of Hsp60 in tumor cells and its role in tumor
progression.
Introduction
Primary brain tumors account for 2% of
human neoplasms in adults and for 20% in
pediatric patients.1 These tumors consist of a
varied group of neoplasms which arise in the
brain and its surrounding structures. The
Word Health Organization (WHO) established
a uniform terminology and grading system for
brain tumors.2 Neuroepithelial tumors, the
most prevalent group, include glioblastoma
multiforme (GBM), medulloblastoma and
astrocytoma, while tumors of the meninges
include meningioma. 
Astrocytomas are classified into four grades.
Pylocitic astrocytoma (grade I) usually occurs
in children or young adults, while astocytomas
of other grades are typically diagnosed in
adults.1,3 GBM is the most common and dead-
liest malignant primary brain tumor in adults,
classified as grade IV astrocytoma.
Medulloblastoma is the most common embry-
onal tumor (these are tumors that arise from
embryonal or immature cells at the earliest
stage of their development);3 it occurs in chil-
dren and young adults. Meningiomas are
tumors of meningothelial cells; they appear in
childhood or adolescence, but most are diag-
nosed in middle or later adult life. Atypical
meningiomas (grade II) show more cellularity,
mitotic activity and foci of necrosis than grade
I meningiomas.1,3
Heat shock proteins (Hsps) are a class of
molecules highly conserved during evolution
with crucial roles in tissue homeostasis.4 Due
to their importance for cell survival and func-
tion, it has been postulated that they may be
involved in the development of a number of
human diseases, now called chaper-
onopathies.4 Some forms of tumors are now
considered chaperonopathies by collaboration,
since chaperones favor the tumor (e.g., by
inhibiting tumor cell apoptosis and/or antitu-
mor immune response) rather than the host
organism.5-8 The presence and levels of various
Hsps in human brain tumors have not been
extensively investigated to date. We conducted
a study on a subset of human brain neoplasms
to compare the levels of two Hsps considered
among the most important players during car-
cinogenesis.
Materials and Methods
Sixty brain tumors, including both neuroep-
ithelial and meningeal neoplasms, classified
accordingly to the WHO parameters, were ret-
rospectively collected from files of the
Pathologic Anatomy Unit of the Civico
Hospital, Palermo, Italy. In particular, we ran-
domly selected ten pilocytic astrocytomas
[female:male (F:M) ratio = 1:4; age range: 4-
17 yrs], ten grade II astrocytomas (F:M ratio =
1:1; age range: 27-84 yrs), ten glioblastoma
multiformae (F:M ratio = 4:1; age range: 44-73
yrs), ten medulloblastomas (F:M ratio = 2:3;
age range: 8-23 yrs), ten grade I meningiomas
(F:M ratio = 4:1; age range: 41-76 yrs), and ten
grade II meningiomas (F:M ratio = 1:1; age
range: 59-77 yrs). Moreover, we selected five
normal brain samples (F:M ratio = 1:1; age
range: 4-85 yrs) from our files, and obtained
slides showing normal glial cells, neurons and
meningeal (pial) cells to be used as normal
controls. All the specimens had been previous-
ly formalin-fixed and paraffin-embedded. 
We obtained sections of a thickness of 4-5
µm from all specimens for histological re-eval-
uation and immunohistochemical testing. The
histological re-evaluation was performed on
haematoxylin-eosin stained slides. Immuno -
staining and statistic analysis was performed
as already described.9 The primary antibodies
used were anti-Hsp60 (mouse monoclonal
antibody, dilution 1:400, Cat. No. H4149, Sigma
Co., Saint Louis, MO, USA), and anti-Hsp70
(mouse monoclonal antibody, dilution 1:200,
Cat. No. SC-24, Santa Cruz Biotechnology,
Dallas, TX, USA). Appropriate positive controls,
as well as non-immune serum for negative
controls, were run concurrently. Immunostai -
ning evaluations were performed by two blind-
ed expert pathologists (FR, NS) and the per-
centage of positive tumor cells was calculated
in ten random high power fields at a magnifi-
cation of 400x.
Statistical analyses were performed as
already described.10 Briefly, we used the Mann-
Whitney U-test for comparison between groups
and the Kruskal-Wallis test for multiple com-
parisons. Probability values of P<0.05 were
considered significant.
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Results and Discussion
Statistical analyses of the immunohisto-
chemical experiments showed that Hsp60 lev-
els were significantly higher P<0.01) than
those of Hsp70 in neuroepithelial tumors
(Figure 1), while levels of both molecules did
not show any significant difference from each
other in meningeal neoplasms (P>0.05). In
particular, Hsp60 immunopositivity was pres-
ent mainly at the cytoplasmic level, while
Hsp70 immunopositivity was found both in the
cytoplasm and nucleus of tumor cells (Figures
2 and 3). The levels of these molecules in the
normal control cells were always very low
(Figures 2 and 3, insets). Finally, the levels of
Hsp60 and Hsp70 did not correlate with the dif-
ferent types (WHO grade) of neoplasm (data
not shown).
Our results are partially in agreement with
previous studies;11-13 in particular, Kato and col-
leagues11 found Hsp60 immunopositivity in a
number of brain tumors, while no significant
immunohistochemical reactions were seen in
sections of normal brain tissue. Batistatou et
al.12 found Hsp70 presence in glial tumors,
mainly in the cytosol, and described a statisti-
cally significant association of the cytosolic
Hsp70 expression with a nuclear expression of
the BCL2-associated Athano-Gene 1 (BAG1)
protein. Finally, Hauser et al.13 described
Hsp70, Hsp27 and Hsp90 positivity in medul-
loblastomas, with no association with tumor
prognosis, indicating these proteins as a puta-
tive molecular target for anticancer therapy. 
Hsp60 is classically considered a mitochon-
drial molecule, while Hsp70 is commonly pres-
ent in the cytosol. The presence of a diffuse
immunohistochemical positivity for Hsp60 in
the cytoplasm, as well as a nuclear positivity
for Hsp70, have already been described in
other forms of solid tumors14-16 and have been
correlated with tumor progression.15-18 The sig-
nificant difference between Hsp60 and Hsp70
levels specific to neuroepithelial tumors may
suggest that the former is not increased by a
passive phenomenon (e.g., due to the stress
caused by the peritumor environment on can-
cer cells) but it may instead be actively impli-
cated in tumor progression, e.g. by inhibiting
tumor cell death or favoring tumor progression
by inhibiting the antitumor response of the
immune system, as already postulated in
vitro.5,8,19 Moreover, these data confirm that
Hsp60 may have different levels and expres-
sion than Hsp70 in different neoplasms,
including head and neck cancer,20 salivary
gland tumors21 and esophageal adenocarcino-
mas.22 However, its participation in meningeal
tumor pathogenesis needs to be further inves-
tigated also with the use other techniques like
proteomics.23
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Figure 2. Representative pictures of immunohistochemical analyses for Hsp60 and Hsp70 in
brain neuroepithelial tumours. Insets show normal control cell positivity. Scale bar: 50 µm. 
Figure 1. Statistical analysis of the immunohistochemistry results for Hsp60 and Hsp70
in brain tumors. The immunopositivity of Hsp60 was elevated in all brain tumor types
studied, while Hsp70 immunopositivity was found to be very low in neuroepithelial
tumors. In the latter, Hsp60 levels were significantly higher than those of Hsp70. In con-
trast, in meningiomas, the expression of both Hsp60 and Hsp70 was elevated, without
significant differences between them. Finally, the expression of these proteins in healthy
control cells was very low. Asterisks indicate statistical significant difference between
Hsp60 and Hsp70 (P<0.01). 
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Indeed, various studies using different tech-
niques have found Hsp60 expression to be
increased, decreased or unchanged in several
tumors of different anatomical districts.16,24
Furthermore, an increase in Hsp60 expression
may correlate either with a more favorable or a
worse prognosis.16,17 From a molecular point of
view, when increased Hsp60 accumulate in the
cytosol where it may have either a pro- or  an
anti-apoptotic action, depending on whether it
has been released by mitochondria or accumu-
lated in the cytosol without mitochondrial
import, respectively.25 For these reasons,
Hsp60 has been proposed as the molecular
Proteus of carcinogenesis.26 In addition, when
accumulated in the cytosol, Hsp60 may trans-
fer to the plasma membrane of tumor cells, in
turn becoming internalized by lipid rafts in
multivesicular bodies and secreted by exo-
somes.7,8 Finally, some anticancer drugs cause
the release of exosomes loaded with Hsp60,
which elicit effective natural killer cell antitu-
mor responses, in vitro.27
In our opinion, we are not far from fully
understanding the mechanisms by which
Hsp60 participates in tumor progression.
Molecular studies concerning post-translation-
al modifications that cytosolic Hsp60 under-
goes when accumulating in the cytosol of
tumor cells could help to fully characterize this
“roteiform molecule. 
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